KRN5500 FDA Approval Status
FDA Approved: No
Brand name: KRN5500
Company: Midatech Pharma US Inc.
Treatment for: Chronic Chemotherapy Induced Peripheral Neuropathy
KRN5500 is a novel, intravenous, non-opioid, non-narcotic compound in development for the treatment of painful, chronic, chemotherapy-induced peripheral neuropathy (CCIPN) that is refractory to conventional analgesics in patients with cancer.
Development Timeline for KRN5500
|Jun 16, 2014||DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma|
|Nov 29, 2012||DARA BioSciences Announces Submission of KRN5500 to FDA for Orphan Designation|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.